These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20221448)

  • 1. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.
    Appledorn DM; Aldhamen YA; Depas W; Seregin SS; Liu CJ; Schuldt N; Quach D; Quiroga D; Godbehere S; Zlatkin I; Kim S; McCormick JJ; Amalfitano A
    PLoS One; 2010 Mar; 5(3):e9579. PubMed ID: 20221448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.
    Appledorn DM; Aldhamen YA; Godbehere S; Seregin SS; Amalfitano A
    Clin Vaccine Immunol; 2011 Jan; 18(1):150-60. PubMed ID: 21084461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
    Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
    Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunity.
    Aldhamen YA; Seregin SS; Schuldt NJ; Rastall DP; Liu CJ; Godbehere S; Amalfitano A
    J Immunol; 2012 Aug; 189(3):1349-59. PubMed ID: 22745373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
    Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
    J Virol; 2021 May; 95(12):. PubMed ID: 33789991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
    BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodominance of Adenovirus-Derived CD8
    Schöne D; Hrycak CP; Windmann S; Lapuente D; Dittmer U; Tenbusch M; Bayer W
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo.
    Seregin SS; Aldhamen YA; Appledorn DM; Aylsworth CF; Godbehere S; Liu CJ; Quiroga D; Amalfitano A
    PLoS One; 2011; 6(7):e22064. PubMed ID: 21760953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant.
    Li M; Jiang Y; Gong T; Zhang Z; Sun X
    Mol Pharm; 2016 Mar; 13(3):885-94. PubMed ID: 26824411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.
    Wille-Reece U; Wu CY; Flynn BJ; Kedl RM; Seder RA
    J Immunol; 2005 Jun; 174(12):7676-83. PubMed ID: 15944268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses.
    Schuldt NJ; Aldhamen YA; Appledorn DM; Seregin SS; Kousa Y; Godbehere S; Amalfitano A
    PLoS One; 2011; 6(8):e24147. PubMed ID: 21912619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.
    Matthews QL; Fatima A; Tang Y; Perry BA; Tsuruta Y; Komarova S; Timares L; Zhao C; Makarova N; Borovjagin AV; Stewart PL; Wu H; Blackwell JL; Curiel DT
    PLoS One; 2010 Jul; 5(7):e11815. PubMed ID: 20676400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
    Qiu JT; Liu B; Tian C; Pavlakis GN; Yu XF
    J Virol; 2000 Jul; 74(13):5997-6005. PubMed ID: 10846081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
    McGettigan JP; Sarma S; Orenstein JM; Pomerantz RJ; Schnell MJ
    J Virol; 2001 Sep; 75(18):8724-32. PubMed ID: 11507217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-capacity adenoviral vectors circumvent the limitations of ΔE1 and ΔE1/ΔE3 adenovirus vectors to induce multispecific transgene product-directed CD8 T-cell responses.
    Kron MW; Engler T; Schmidt E; Schirmbeck R; Kochanek S; Kreppel F
    J Gene Med; 2011 Dec; 13(12):648-57. PubMed ID: 22095925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
    Kanagavelu SK; Snarsky V; Termini JM; Gupta S; Barzee S; Wright JA; Khan WN; Kornbluth RS; Stone GW
    Vaccine; 2012 Jan; 30(4):691-702. PubMed ID: 22146759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.
    Wanjalla CN; Faul EJ; Gomme EA; Schnell MJ
    Vaccine; 2010 Dec; 29(1):130-40. PubMed ID: 20728525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.